ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. The company's clinical stage candidates include QR-010, a RNA-based oligonucleotide that is in Phase Ib clinical trial for the treatment of cystic fibrosis. It also develops QR-110, which is in pre-clinical development stage for the treatment of Leber's congenital amaurosis. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.
Trade Type
| ReliabilityScore™
| Entry Date
| Entry Price
| Sell Date
| Sell Price
| Net Gain
| Hold Time
|